ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent, selective small molecule inhibitor of the transcription factor NRF2, commonly used to investigate antioxidant signaling and therapeutic resistance in cancer research (APExBIO, B8300). ML385 demonstrates an IC50 of 1.9 μM in cell-based NRF2 activity assays and is effective in both in vitro and in vivo models, particularly for non-small cell lung cancer (NSCLC). The compound modulates NRF2-dependent gene expression and enhances chemosensitivity, especially when combined with agents like carboplatin (Zhou et al., 2024). ML385 is insoluble in water and ethanol, but achieves ≥13.33 mg/mL solubility in DMSO, with optimal storage at -20°C for stability (Product data). The use of ML385 enables researchers to dissect the precise roles of NRF2 in oxidative stress, ferroptosis, and drug resistance across diverse disease models.

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a master regulator of cellular antioxidant responses, detoxification enzymes, and multidrug transporter expression (Zhou et al., 2024). Under homeostatic conditions, NRF2 is bound by KEAP1 and targeted for proteasomal degradation. Upon oxidative or electrophilic stress, NRF2 stabilizes and translocates to the nucleus, where it drives the expression of genes involved in glutathione biosynthesis, NADPH regeneration, and antioxidant defense. Aberrant upregulation of NRF2 is implicated in multiple malignancies, including NSCLC, where it contributes to therapeutic resistance and poor prognosis. Targeted NRF2 inhibition provides a strategy to sensitize cancer cells to chemotherapy and modulate oxidative stress responses, as shown in both cancer and liver disease models (See also—this article extends mechanistic focus to combinatorial therapies).

Mechanism of Action of ML385

ML385 is a selective, non-covalent inhibitor that directly binds the Neh1 DNA-binding domain of NRF2, blocking its interaction with antioxidant response element (ARE) sequences on target gene promoters (APExBIO datasheet). This inhibition leads to dose- and time-dependent downregulation of NRF2-dependent genes, including NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), and glutamate-cysteine ligase catalytic subunit (GCLC). In A549 NSCLC cell lines, ML385 reduces transcriptional activity of NRF2 within 24 hours post-treatment at micromolar concentrations. In vivo, systemic administration of ML385 (100 mg/kg/day, intraperitoneal) suppresses NRF2 signaling and impairs tumor growth. Importantly, ML385 does not significantly inhibit other bZIP transcription factors, supporting its selectivity. See this article for a deeper discussion of ML385’s impact on the tumor microenvironment—this article clarifies benchmark conditions.

Evidence & Benchmarks

• ML385 exhibits an IC50 of 1.9 μM for NRF2 inhibition in A549 cell-based luciferase reporter assays (APExBIO datasheet).
• Systemic dosing of ML385 (100 mg/kg/day, intraperitoneally, 6 weeks) in rodent models suppresses NRF2 target gene expression and impairs tumor growth and metastasis in NSCLC xenografts (Zhou et al., 2024).
• ML385 enhances the efficacy of carboplatin in preclinical NSCLC models, indicating synergy in combination therapy (Product page).
• ML385 is insoluble in water and ethanol but achieves ≥13.33 mg/mL solubility in DMSO at room temperature (APExBIO).
• In alcoholic liver disease (ALD) models, ML385 reverses the protective effects of Poria cocos polysaccharides (PCP) by blocking NRF2-dependent antioxidant and anti-ferroptotic pathways (Zhou et al., 2024).

Applications, Limits & Misconceptions

ML385 is widely used in cancer research, especially for NSCLC, to study NRF2-dependent therapeutic resistance and redox regulation. It is also employed in liver disease models to delineate oxidative stress and ferroptosis pathways. The compound is valuable for dissecting NRF2’s role in detoxification, inflammation, and metabolic regulation. However, ML385’s selectivity for NRF2 means it is not suitable for inhibiting other antioxidant transcription factors. It is optimized for research use only and not for clinical or in vivo therapeutic applications.

For a broader mechanistic context and advanced applications, see ML385 and NRF2 Inhibition: Advanced Insights—this article updates with new evidence from ALD models and combinatorial strategies.

Common Pitfalls or Misconceptions

• ML385 is not effective against non-NRF2-dependent pathways or unrelated bZIP transcription factors.
• ML385’s solubility limitations require careful solvent selection; it is not suitable for aqueous or ethanol-based preparations.
• Long-term storage of ML385 solutions at ambient temperature leads to rapid degradation; always store at -20°C and use freshly prepared solutions.
• ML385 is not validated for human therapeutic use and should only be used in preclinical or cell-based research.
• NRF2-independent resistance mechanisms will not be addressed by ML385 treatment.

Workflow Integration & Parameters

ML385 (B8300, APExBIO) should be dissolved in DMSO to a stock concentration of at least 13.33 mg/mL. Recommended working concentrations in cell culture range from 0.5–10 μM, with higher concentrations used for in vivo studies (e.g., 100 mg/kg/day in rodent models). For in vitro experiments, add ML385 to culture media immediately before use to avoid precipitation. Store all ML385 aliquots at -20°C and minimize freeze-thaw cycles. In combination therapy experiments (e.g., with carboplatin), sequential or concurrent dosing protocols can reveal synergy in NRF2-dependent chemoresistance. Protein and mRNA expression of NRF2 targets (NQO1, HO-1, GCLC) should be monitored by qPCR or immunoblotting as readouts. For more hands-on workflows, see ML385: Selective NRF2 Inhibitor Advancing Cancer Research—this guide details protocols and troubleshooting, while this article provides expanded evidence from new disease models.

Conclusion & Outlook

ML385 is a validated, selective NRF2 inhibitor enabling precise investigation of antioxidant response regulation, cancer therapeutic resistance, and oxidative stress pathways. Its robust performance in NSCLC and liver disease models underscores its value for dissecting NRF2’s multifaceted roles. As new evidence emerges regarding NRF2’s involvement in ferroptosis, detoxification, and redox metabolism, ML385 remains an indispensable tool for preclinical research. The B8300 kit from APExBIO sets the benchmark for NRF2 signaling pathway inhibition, supporting advanced research in oncology and beyond.